Top Page
Zelira Therapeutics
(OTC:ZLD)
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
Zelira Therapeutics Business Overview & Revenue Model
Zelira Therapeutics Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.88K | 94.95K | 301.12K | 1.54M | 663.32K | 0.00 |
| Gross Profit | -285.19K | 10.28K | -3.22M | -5.72M | -39.16K | -275.05K |
| EBITDA | -3.98M | -36.44M | -6.87M | -12.83M | -9.18M | -7.71M |
| Net Income | -4.84M | -36.57M | -5.57M | -11.95M | -8.55M | -7.02M |
Balance Sheet | ||||||
| Total Assets | 2.39M | 5.18M | 33.89M | 37.70M | 39.37M | 35.79M |
| Cash, Cash Equivalents and Short-Term Investments | 38.19K | 586.16K | 146.21K | 2.75M | 4.97M | 1.70M |
| Total Debt | 6.30M | 5.95M | 437.90K | 500.91K | 551.08K | 632.32K |
| Total Liabilities | 10.36M | 9.36M | 2.18M | 2.01M | 1.54M | 1.24M |
| Stockholders Equity | -8.40M | -4.51M | 31.80M | 35.20M | 37.83M | 34.55M |
Cash Flow | ||||||
| Free Cash Flow | -5.29M | -4.39M | -7.25M | -9.43M | -8.62M | -6.95M |
| Operating Cash Flow | -5.29M | -4.39M | -7.25M | -9.43M | -8.62M | -6.94M |
| Investing Cash Flow | 919.74K | 919.74K | 2.83M | -207.78K | 1.38M | 1.11M |
| Financing Cash Flow | 4.36M | 3.92M | 1.77M | 7.10M | 10.53M | 4.50M |
Zelira Therapeutics Technical Analysis
Zelira Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$6.69M | 59.33 | 2.14% | ― | ― | ― | |
54 Neutral | AU$26.61M | 9.76 | 26.99% | ― | ― | 51.85% | |
48 Neutral | AU$2.43B | 4.28 | -64.25% | 2.88% | 36.51% | 13.13% | |
46 Neutral | AU$2.14M | ― | -392.18% | ― | ― | 34.26% | |
46 Neutral | AU$5.23M | ― | -263.02% | ― | -85.34% | 86.74% | |
46 Neutral | AU$12.69M | ― | -64.72% | ― | 139.19% | 33.33% |
Zelira Therapeutics Corporate Events
Zelira Therapeutics announced the publication of a clinical study demonstrating the efficacy and safety of its proprietary cannabinoid-based therapy, ZLT-L-007, in treating diabetic neuropathy. The study showed that ZLT-L-007 significantly outperformed Lyrica® (Pregabalin) in reducing pain and improving quality of life for patients, marking a potential shift in the standard-of-care treatment for diabetic neuropathy. The study, conducted under rigorous clinical standards, reported no serious adverse events, suggesting a promising future for ZLT-L-007 in the market.
Zelira Therapeutics has enhanced its financial flexibility by receiving a $1.15 million R&D Tax Incentive refund and establishing a $1 million At-the-Market funding facility. These financial moves support its ongoing development programs, including preparations for the FDA clinical trial of HOPE® 1. The company also completed the full conversion of US$3.25 million convertible notes into equity, strengthening its capital structure. The development of capsule formulations for HOPE® and Zenivol® using Zyraydi™ technology is on track for completion in mid to late 2025, aligning with Zelira’s strategy to enhance product consistency and market readiness.
Zelira Therapeutics has announced the full conversion of $USD3.25 million in Convertible Notes into equity within its HOPE® 1 SPV, which supports the clinical and regulatory development of treatments for Autism Spectrum Disorder. This conversion aligns investor interests, eliminates debt obligations, and strengthens the SPV’s capital structure, positioning it well for future institutional capital raises. The company has made significant progress in its clinical trial program, having completed a Pre-IND meeting with the U.S. FDA, which confirmed the appropriateness of targeting Phelan-McDermid Syndrome, a rare subset of Autism, for study. Zelira is now focused on submitting an IND to the FDA, initiating Phase 1 clinical trials, and filing for Orphan Drug Designation to leverage regulatory incentives.
Zelira Therapeutics has released an investor deck highlighting its position in the biopharmaceutical industry, focusing on cannabinoid-based medicines. The announcement underscores the company’s strategic market positioning and potential for value creation, appealing to investors interested in the burgeoning global market.
Zelira Therapeutics Limited has announced the quotation of 550,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code ZLD. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations, which could impact its positioning in the pharmaceutical industry.
Zelira Therapeutics Limited has issued a prospectus for an offer of up to 1,000 shares at $0.50 each, aiming to raise $500 before expenses. This transaction-specific prospectus is designed to remove secondary trading restrictions on shares issued under a facility agreement with Securities Vault Pty Ltd, and the offer closes on April 4, 2025. The shares are considered speculative, and the prospectus is not for distribution in the United States.
Zelira Therapeutics Limited announced a proposed issue of 550,000 ordinary fully paid securities, with the issue date set for March 31, 2025. This move is part of the company’s strategic efforts to enhance its financial position and support its ongoing projects, potentially impacting its market presence and stakeholder interests positively.
Zelira Therapeutics has secured a $1 million At-the-Market (ATM) funding facility with Securities Vault Pty Ltd to support its clinical programs and growth strategy. This facility provides Zelira with flexible access to equity capital over the next 12 months, allowing the company to align capital needs with operational activities while maintaining control over the timing and terms of capital issuances. The ATM agreement enhances Zelira’s financial flexibility and positions the company to advance its strategic objectives without incurring significant dilution or complex financing mechanisms.